Astria Therapeutics, Inc.
ATXSInactive ticker- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001454789
No open-market purchases or sales by Astria Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Astria Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Astria Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kishbauch Michael D | Director | – | Jan 23, 2026 | 1 |
| Bate Kenneth | Director | – | Jan 23, 2026 | 1 |
| Lapointe Anthony Gregg | Director | – | Jan 23, 2026 | 1 |
| Cole Hugh M | Director | – | Jan 23, 2026 | 1 |
| Agarwal Sunil | Director | – | Jan 23, 2026 | 1 |
| Milne Jill C. | CEO and President | 0 | Jan 23, 2026 | 1 |
| Harshbarger Benjamin | Chief Legal Officer | – | Jan 23, 2026 | 1 |
| Violin Jonathan | Director | 0 | Jan 23, 2026 | 1 |
| Beck Joanne T. | Director | – | Jan 23, 2026 | 1 |
| Komjathy Andrew | Chief Commercial Officer | 0Indirect | Jan 23, 2026 | 1 |
| Clauser Noah | Chief Financial Officer | – | Jan 23, 2026 | 1 |
| Callori Fred | Director | – | Jan 23, 2026 | 1 |
| Morabito Christopher | Chief Medical Officer | 0 | Jan 23, 2026 | 1 |
| Matthews Andrea | Chief Business Officer | – | Jan 23, 2026 | 1 |
| Edelman Joseph | Director | 4,873,721Indirect | Feb 5, 2024 | 0 |
| Perceptive Advisors LLC | Director | 4,873,721Indirect | Feb 5, 2024 | 0 |
| Perceptive Life Sciences Master Fund Ltd | Director | 4,873,721Indirect | Feb 5, 2024 | 0 |
| Perceptive Xontogeny Venture Fund, LP | Director | 4,873,721Indirect | Feb 5, 2024 | 0 |
| Nichols Andrew John | Chief Scientific Officer | – | Mar 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Morabito ChristopherChief Medical Officer | SSale | −10.0K | $13.59 | −$135.9K | −100.0%0 after | 10b5-1 |
| Feb 5, 2024 (view filing)5:02 PM ET | Feb 1 | 4 days | Edelman Joseph and 3 othersDirector | PPurchase | +2.48M | $12.09 | +$30.0M | +103.7%4.87M after | |
| Jan 30, 2024 (view filing) | Jan 26-29 | 4 days | Morabito ChristopherChief Medical Officer | SSale | −10.0K | $11.14 | −$111.4K | −100.0%0 after | 2 lots10b5-1 |
| Dec 22, 2023 (view filing)2:51 PM ET | Dec 21 | 1 day | Edelman Joseph and 3 othersDirector | PPurchase | +740.0K | $6.20 | +$4.59M | +44.8%2.39M after | |
| Oct 18, 2023 (view filing)4:11 PM ET | Oct 16 | 2 days | Edelman Joseph and 3 othersDirector | PPurchase | +1.07M | $6.51 | +$7.00M | +200.1%1.61M after | 2 lots |
| Oct 18, 2023 (view filing)4:11 PM ET | Oct 16 | 2 days | Edelman Joseph and 3 othersDirector | PPurchase | +2.42M | $7.86 | +$19.0M | –345.4K after | Derivative4 lots |
| Dec 21, 2022 (view filing)4:52 PM ET | Dec 19 | 2 days | Edelman Joseph and 3 othersDirector | PPurchase | +908.3K | $11.01 | +$10.0M | +698.4%1.04M after | |
| Nov 23, 2021 (view filing) | Nov 19 | 4 days | Komjathy AndrewChief Commercial Officer | PPurchase | +100 | $6.70 | +$670 | New position100 after |